PubMed Health⌕ Search

Biomedical subjects

A Scarinci

Publications and source records attributed to A Scarinci.

11 recordsLinked to original sources

Endomyocardial infiltration by B and NK cells foreshadows the recurrence of cardiac allograft rejection.

Heart allograft outcome is unpredictable and acute rejection episodes still occur despite the improvement of immunosuppressive regimens. We therefore investigated whether the immunopathological profile of endomyocardial biopsies might underlie the variations in the clinical course of a graft. Biopsies from transplanted patients were analysed by histology, immunohistochemistry (associated with digital image analysis), confocal and electron microscopy to determine the type and the functional state of leukocytes infiltrating the myocardium, together with their ultrastructural features and those of the graft itself. In comparison with biopsies with grade 0R or grade 1R rejection, those from patients with grade 2R rejection displayed significant infiltration of macrophages, T lymphocytes, and CD83+ and DC-SIGN+ dendritic cells. Fifty-seven per cent were invaded by CD20+B lymphocytes, most of which expressed CD69 activation marker and cooperated in interleukin-12 production, and by CD69+CD94+NK cells expressing interferon-gamma. Ultrastructural signs of myocyte degeneration and microvessel rupture by NK cells were frequent. These patients developed recurrent episodes of acute allograft rejection. Endomyocardial B and NK infiltrates are involved in the dynamics of allograft rejection and are associated with a high risk of its recurrence. Immunopathological assessment of endomyocardial biopsies may thus serve to forecast the probable outcome of a heart allograft.

Adult↗

[Cardiopathy in uremic dialyzed patients: transthoracic and transesophageal echocardiography].

BACKGROUND: Despite progress and improvement in the dialysis modalities, cardiovascular disease remains the leading cause of death in patients receiving chronic hemodialysis therapy. METHODS: To determine the prevalence of myocardial abnormalities among these patients, thirty-nine patients (22 males and 17 females, ranging in age from 20 to 87; mean age 61.38 +/- 15.04) underwent echocardiographic study. Twenty-seven were also examined by transesophageal echocardiogram. The morphology and function of the left ventricle as well as the presence of pericardial effusion, valvular disease and calcification were examined. The data obtained from transthoracic and transesophageal echocardiography were then compared. RESULTS: The patients on chronic hemodialysis treatment showed a high prevalence of valvular disease (observed in 90% of the cases, but rarely hemodynamically relevant), calcifications (74%) and left ventricular hypertrophy (74%). Impaired cardiac function (diastolic dysfunction in 74% of the patients; systolic dysfunction in 36%) and left atrial enlargement (50%) were frequently observed. The incidence rates of pericardial effusion (7%) left atrial thrombi (7%) and atherosclerotic plaques of coronary arteries (10%) were uncommon. CONCLUSIONS: Transesophageal echocardiography is more accurate than transthoracic echocardiography in evaluating the presence of cardiac calcification (particularly of mitral apparatus), valvular leaflet mobility minor valvular regurgitation, left atrial and auricolar thrombi and spontaneous echocontrast, aortic and interatrial septum abnormalities and coronary artery atherosclerotic plaque.

Adult↗

Acute cardiotoxicity during capecitabine treatment: a case report.

Capecitabine (Xeloda, Roche, Monza), a fluoropyrimidine carbamate, is an orally administered drug that delivers fluorouracil (5-FU) selectively to the tumor. The drug has demonstrated activity in metastatic breast cancer, pancreatic cancer and colorectal cancer. In this case report the authors describe an unusually and reversible cardiac side effect which occurs to 39-year-old patient treated with capecitabine 2000 mg/m2/day for advanced gastric cancer. It is important to note that the safety data from clinical trials indicate that capecitabine has a toxicity profile typical of infused fluoropyrimidines. However, none of the studies described cardiac side effects.

Acute Disease↗

[Acute cardiotoxicity from 5-fluorouracil: un underestimated toxicity].

The most common toxicity in clinical trials with 5-FU, in mono or polychemotherapy, is stomatitis, diarrhea, hand-foot syndrome. In this case report, the 5-fluorouracil (5-FU) cardiotoxicity, an uncommon 5-FU-related toxicity, has been investigated. Cardiotoxicity reports are uncommon because the problem is not well known. This study is also a review of the recent literature and it recommend to take care in prescribing chemotherapy to patients with heart disease history.

Antineoplastic Combined Chemotherapy Protocols↗